Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-08-13

AUTHORS

Antonio Nicolucci, Riccardo Candido, Domenico Cucinotta, Giusi Graziano, Alberto Rocca, Maria C. Rossi, Franco Tuccinardi, Valeria Manicardi

ABSTRACT

IntroductionFollowing the US Food and Drug Administration (FDA) guidance on the evaluation of novel agents for the treatment of type 2 diabetes mellitus (T2DM), a number of cardiovascular outcomes safety trials (CVOTs) on sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been conducted. These trials show similarities in study design and definition of primary endpoints, but differ in their eligibility criteria. The aim of the present study was to investigate the generalizability of CVOTs on SGLT2i to Italian adults with T2DM; we estimated the proportions of this patient population who would be eligible for enrollment in EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin), DECLARE-TIMI 58 (dapagliflozin), and VERTIS-CV (ertugliflozin) studies.MethodsThis observational, cross-sectional study was conducted in 222 Italian diabetes clinics. Data on 455,662 adult patients with T2DM seen during 2016 were analyzed against the published patient eligibility criteria for the four CVOTs. The current use of SGLT2i in potentially eligible patients was assessed.ResultsAmong the population identified, the proportion of patients meeting major eligibility criteria was 11.7% for EMPA-REG OUTCOME, 29.4% for CANVAS, 55.9% for DECLARE-TIMI 58, and 12.8% for VERTIS-CV. Of the patients eligible for these CVOTs, only a minority (range 4.4–6.8%) was actually prescribed an SGLT2i. Compared with patients in the CVOTs, eligible patients in the real world showed older age and longer diabetes duration, lower BMI and HbA1c levels, lower prevalence of established cardiovascular and cerebrovascular disease, and higher rates of microvascular complications and peripheral arterial disease.ConclusionThe percentage of patients potentially eligible for treatment with SGLT2i varies as a reflection of different eligibility criteria applied in the trials. A large number of patients that could benefit from SGLT2i in terms of not only cardiovascular protection but also renal protection do not receive the treatment.FundingAstraZeneca. More... »

PAGES

2895-2909

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12325-019-01043-z

DOI

http://dx.doi.org/10.1007/s12325-019-01043-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1120311915

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31410779


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzhydryl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Canagliflozin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Sectional Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucosides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sodium-Glucose Transporter 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sodium-Glucose Transporter 2 Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy", 
          "id": "http://www.grid.ac/institutes/grid.512242.2", 
          "name": [
            "CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nicolucci", 
        "givenName": "Antonio", 
        "id": "sg:person.01112613263.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112613263.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centro Diabetologico Distretto 3, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy", 
          "id": "http://www.grid.ac/institutes/grid.460062.6", 
          "name": [
            "Centro Diabetologico Distretto 3, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Candido", 
        "givenName": "Riccardo", 
        "id": "sg:person.01026702544.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026702544.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dipartimento di Medicina Clinica e Sperimentale, Universit\u00e0 di Messina, Messina, Italy", 
          "id": "http://www.grid.ac/institutes/grid.10438.3e", 
          "name": [
            "Dipartimento di Medicina Clinica e Sperimentale, Universit\u00e0 di Messina, Messina, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cucinotta", 
        "givenName": "Domenico", 
        "id": "sg:person.01232501740.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232501740.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy", 
          "id": "http://www.grid.ac/institutes/grid.512242.2", 
          "name": [
            "CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Graziano", 
        "givenName": "Giusi", 
        "id": "sg:person.0637110453.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637110453.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Struttura Semplice Diabetologia e Malattie Metaboliche \u201cGiovanni Segalini\u201d, Ospedale Bassini, Cinisello Balsamo, ASST Nord Milano, Miano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414266.3", 
          "name": [
            "Struttura Semplice Diabetologia e Malattie Metaboliche \u201cGiovanni Segalini\u201d, Ospedale Bassini, Cinisello Balsamo, ASST Nord Milano, Miano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rocca", 
        "givenName": "Alberto", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy", 
          "id": "http://www.grid.ac/institutes/grid.512242.2", 
          "name": [
            "CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rossi", 
        "givenName": "Maria C.", 
        "id": "sg:person.010041300312.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010041300312.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Struttura Complessa Diabetologia, Ospedale di Formia, Azienda USL Latina, Formia, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Struttura Complessa Diabetologia, Ospedale di Formia, Azienda USL Latina, Formia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tuccinardi", 
        "givenName": "Franco", 
        "id": "sg:person.010035354133.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010035354133.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AMD Annals Coordinator, Reggio Emilia, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "AMD Annals Coordinator, Reggio Emilia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Manicardi", 
        "givenName": "Valeria", 
        "id": "sg:person.0642244236.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0642244236.63"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00592-014-0688-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027960230", 
          "https://doi.org/10.1007/s00592-014-0688-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-019-4839-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1112731482", 
          "https://doi.org/10.1007/s00125-019-4839-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-015-3547-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048430137", 
          "https://doi.org/10.1007/s00125-015-3547-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-08-13", 
    "datePublishedReg": "2019-08-13", 
    "description": "IntroductionFollowing the US Food and Drug Administration (FDA) guidance on the evaluation of novel agents for the treatment of type 2 diabetes mellitus (T2DM), a number of cardiovascular outcomes safety trials (CVOTs) on sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been conducted. These trials show similarities in study design and definition of primary endpoints, but differ in their eligibility criteria. The aim of the present study was to investigate the generalizability of CVOTs on SGLT2i to Italian adults with T2DM; we estimated the proportions of this patient population who would be eligible for enrollment in EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin), DECLARE-TIMI 58 (dapagliflozin), and VERTIS-CV (ertugliflozin) studies.MethodsThis observational, cross-sectional study was conducted in 222 Italian diabetes clinics. Data on 455,662 adult patients with T2DM seen during 2016 were analyzed against the published patient eligibility criteria for the four CVOTs. The current use of SGLT2i in potentially eligible patients was assessed.ResultsAmong the population identified, the proportion of patients meeting major eligibility criteria was 11.7% for EMPA-REG OUTCOME, 29.4% for CANVAS, 55.9% for DECLARE-TIMI 58, and 12.8% for VERTIS-CV. Of the patients eligible for these CVOTs, only a minority (range 4.4\u20136.8%) was actually prescribed an SGLT2i. Compared with patients in the CVOTs, eligible patients in the real world showed older age and longer diabetes duration, lower BMI and HbA1c levels, lower prevalence of established cardiovascular and cerebrovascular disease, and higher rates of microvascular complications and peripheral arterial disease.ConclusionThe percentage of patients potentially eligible for treatment with SGLT2i varies as a reflection of different eligibility criteria applied in the trials. A large number of patients that could benefit from SGLT2i in terms of not only cardiovascular protection but also renal protection do not receive the treatment.FundingAstraZeneca.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12325-019-01043-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096634", 
        "issn": [
          "0741-238X", 
          "1865-8652"
        ], 
        "name": "Advances in Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "keywords": [
      "sodium-glucose cotransporter 2 inhibitors", 
      "EMPA-REG OUTCOME", 
      "eligibility criteria", 
      "eligible patients", 
      "safety trial", 
      "type 2 diabetes mellitus", 
      "Italian diabetes clinics", 
      "major eligibility criteria", 
      "cardiovascular safety trials", 
      "cotransporter 2 inhibitors", 
      "proportion of patients", 
      "peripheral arterial disease", 
      "percentage of patients", 
      "patient eligibility criteria", 
      "cross-sectional study", 
      "different eligibility criteria", 
      "VERTIS CV", 
      "primary endpoint", 
      "microvascular complications", 
      "renal protection", 
      "diabetes clinic", 
      "adult patients", 
      "diabetes mellitus", 
      "arterial disease", 
      "SGLT2 inhibitors", 
      "lower BMI", 
      "cerebrovascular disease", 
      "cardiovascular protection", 
      "patient population", 
      "Drug Administration guidance", 
      "novel agents", 
      "low prevalence", 
      "patients", 
      "US Food", 
      "clinical practice", 
      "older age", 
      "study design", 
      "trials", 
      "T2DM", 
      "Administration guidance", 
      "high rate", 
      "treatment", 
      "disease", 
      "Italian adults", 
      "current use", 
      "present study", 
      "outcomes", 
      "inhibitors", 
      "mellitus", 
      "MethodsThis", 
      "BMI", 
      "complications", 
      "ResultsAmong", 
      "clinic", 
      "criteria", 
      "population", 
      "prevalence", 
      "proportion", 
      "endpoint", 
      "study", 
      "adults", 
      "age", 
      "enrollment", 
      "duration", 
      "generalizability", 
      "aim", 
      "protection", 
      "agents", 
      "percentage", 
      "food", 
      "levels", 
      "minority", 
      "evaluation", 
      "number", 
      "rate", 
      "large number", 
      "guidance", 
      "use", 
      "practice", 
      "data", 
      "implications", 
      "definition", 
      "canvases", 
      "world", 
      "real world", 
      "similarity", 
      "terms", 
      "design", 
      "reflection"
    ], 
    "name": "Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice", 
    "pagination": "2895-2909", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1120311915"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12325-019-01043-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31410779"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12325-019-01043-z", 
      "https://app.dimensions.ai/details/publication/pub.1120311915"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_830.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12325-019-01043-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-01043-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-01043-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-01043-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-01043-z'


 

This table displays all metadata directly associated to this object as RDF triples.

289 TRIPLES      22 PREDICATES      134 URIs      123 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12325-019-01043-z schema:about N0b7c5ab21a5847bc990fc6b35e195dfa
2 N1739deedd3cf49c58a2762af54201925
3 N1f64528249fc42b299bc57d48c61d6fb
4 N20ca2f9d1d1a490980c9b679dfeb8c0d
5 N2382def0314a48899880b483566ec955
6 N29d2ec45478a49f3b8e3aa1754c3f600
7 N4c52fac02dfb4782b666a9937c228ffe
8 N5cbbfb7974e1466181549aba803a9d5d
9 N8a21ec441b784f96abbdcb40e22d6098
10 N95d963390c71401e9a72c322a1837be4
11 N9f24e8807532439180db295cafb4c2dd
12 Nb495d32894e04b4db692cf5a12ffdffb
13 Nba4365c82c0a4c4ebb79658e3ccdd550
14 Nc31c4a3dc60245d987aad679f6a80fbe
15 Nd12ed3a937ed4aada5fc2c0a68f0398e
16 Ne57ae46fabb04809b99e779846c9996b
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N0a074b1301a0442aae0524c1e42fa9d7
20 schema:citation sg:pub.10.1007/s00125-015-3547-2
21 sg:pub.10.1007/s00125-019-4839-8
22 sg:pub.10.1007/s00592-014-0688-6
23 schema:datePublished 2019-08-13
24 schema:datePublishedReg 2019-08-13
25 schema:description IntroductionFollowing the US Food and Drug Administration (FDA) guidance on the evaluation of novel agents for the treatment of type 2 diabetes mellitus (T2DM), a number of cardiovascular outcomes safety trials (CVOTs) on sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been conducted. These trials show similarities in study design and definition of primary endpoints, but differ in their eligibility criteria. The aim of the present study was to investigate the generalizability of CVOTs on SGLT2i to Italian adults with T2DM; we estimated the proportions of this patient population who would be eligible for enrollment in EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin), DECLARE-TIMI 58 (dapagliflozin), and VERTIS-CV (ertugliflozin) studies.MethodsThis observational, cross-sectional study was conducted in 222 Italian diabetes clinics. Data on 455,662 adult patients with T2DM seen during 2016 were analyzed against the published patient eligibility criteria for the four CVOTs. The current use of SGLT2i in potentially eligible patients was assessed.ResultsAmong the population identified, the proportion of patients meeting major eligibility criteria was 11.7% for EMPA-REG OUTCOME, 29.4% for CANVAS, 55.9% for DECLARE-TIMI 58, and 12.8% for VERTIS-CV. Of the patients eligible for these CVOTs, only a minority (range 4.4–6.8%) was actually prescribed an SGLT2i. Compared with patients in the CVOTs, eligible patients in the real world showed older age and longer diabetes duration, lower BMI and HbA1c levels, lower prevalence of established cardiovascular and cerebrovascular disease, and higher rates of microvascular complications and peripheral arterial disease.ConclusionThe percentage of patients potentially eligible for treatment with SGLT2i varies as a reflection of different eligibility criteria applied in the trials. A large number of patients that could benefit from SGLT2i in terms of not only cardiovascular protection but also renal protection do not receive the treatment.FundingAstraZeneca.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N43fe53a1f93a420ebb1df522e1fbbba9
30 N4466766c79554d9a86db2e547f9e3126
31 sg:journal.1096634
32 schema:keywords Administration guidance
33 BMI
34 Drug Administration guidance
35 EMPA-REG OUTCOME
36 Italian adults
37 Italian diabetes clinics
38 MethodsThis
39 ResultsAmong
40 SGLT2 inhibitors
41 T2DM
42 US Food
43 VERTIS CV
44 adult patients
45 adults
46 age
47 agents
48 aim
49 arterial disease
50 canvases
51 cardiovascular protection
52 cardiovascular safety trials
53 cerebrovascular disease
54 clinic
55 clinical practice
56 complications
57 cotransporter 2 inhibitors
58 criteria
59 cross-sectional study
60 current use
61 data
62 definition
63 design
64 diabetes clinic
65 diabetes mellitus
66 different eligibility criteria
67 disease
68 duration
69 eligibility criteria
70 eligible patients
71 endpoint
72 enrollment
73 evaluation
74 food
75 generalizability
76 guidance
77 high rate
78 implications
79 inhibitors
80 large number
81 levels
82 low prevalence
83 lower BMI
84 major eligibility criteria
85 mellitus
86 microvascular complications
87 minority
88 novel agents
89 number
90 older age
91 outcomes
92 patient eligibility criteria
93 patient population
94 patients
95 percentage
96 percentage of patients
97 peripheral arterial disease
98 population
99 practice
100 present study
101 prevalence
102 primary endpoint
103 proportion
104 proportion of patients
105 protection
106 rate
107 real world
108 reflection
109 renal protection
110 safety trial
111 similarity
112 sodium-glucose cotransporter 2 inhibitors
113 study
114 study design
115 terms
116 treatment
117 trials
118 type 2 diabetes mellitus
119 use
120 world
121 schema:name Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice
122 schema:pagination 2895-2909
123 schema:productId N49d6d75f1eaf47518fecd685f8f228c5
124 N8ef9d4300b3d4bbf86d333deadebfc02
125 Nbe16eb71cddd435b8a8512b8eb0a70db
126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1120311915
127 https://doi.org/10.1007/s12325-019-01043-z
128 schema:sdDatePublished 2022-05-20T07:35
129 schema:sdLicense https://scigraph.springernature.com/explorer/license/
130 schema:sdPublisher Nc8d65dc4b636476898485c02045de4ca
131 schema:url https://doi.org/10.1007/s12325-019-01043-z
132 sgo:license sg:explorer/license/
133 sgo:sdDataset articles
134 rdf:type schema:ScholarlyArticle
135 N0a074b1301a0442aae0524c1e42fa9d7 rdf:first sg:person.01112613263.43
136 rdf:rest Nc428835ba90a400ca15544cab29748a5
137 N0b7c5ab21a5847bc990fc6b35e195dfa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Cross-Sectional Studies
139 rdf:type schema:DefinedTerm
140 N1739deedd3cf49c58a2762af54201925 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Diabetes Mellitus, Type 2
142 rdf:type schema:DefinedTerm
143 N1f64528249fc42b299bc57d48c61d6fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Cardiovascular Diseases
145 rdf:type schema:DefinedTerm
146 N2063f8d8331143c18ac3976c67c91a09 rdf:first N699181b083f44f7eacc5430a07f0d13e
147 rdf:rest Ne275c273769845cfa056c419cb0f56fe
148 N20ca2f9d1d1a490980c9b679dfeb8c0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Benzhydryl Compounds
150 rdf:type schema:DefinedTerm
151 N2382def0314a48899880b483566ec955 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Aged, 80 and over
153 rdf:type schema:DefinedTerm
154 N29d2ec45478a49f3b8e3aa1754c3f600 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Canagliflozin
156 rdf:type schema:DefinedTerm
157 N3968a71f609f44b2aff38e74c0d3233b rdf:first sg:person.010035354133.81
158 rdf:rest Nce289f0332f5494d8478060a7bf5b198
159 N43fe53a1f93a420ebb1df522e1fbbba9 schema:issueNumber 10
160 rdf:type schema:PublicationIssue
161 N4466766c79554d9a86db2e547f9e3126 schema:volumeNumber 36
162 rdf:type schema:PublicationVolume
163 N49d6d75f1eaf47518fecd685f8f228c5 schema:name pubmed_id
164 schema:value 31410779
165 rdf:type schema:PropertyValue
166 N4c52fac02dfb4782b666a9937c228ffe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Hypoglycemic Agents
168 rdf:type schema:DefinedTerm
169 N5cbbfb7974e1466181549aba803a9d5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Sodium-Glucose Transporter 2
171 rdf:type schema:DefinedTerm
172 N699181b083f44f7eacc5430a07f0d13e schema:affiliation grid-institutes:grid.414266.3
173 schema:familyName Rocca
174 schema:givenName Alberto
175 rdf:type schema:Person
176 N8a21ec441b784f96abbdcb40e22d6098 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Male
178 rdf:type schema:DefinedTerm
179 N8ef9d4300b3d4bbf86d333deadebfc02 schema:name dimensions_id
180 schema:value pub.1120311915
181 rdf:type schema:PropertyValue
182 N95d963390c71401e9a72c322a1837be4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Aged
184 rdf:type schema:DefinedTerm
185 N9f24e8807532439180db295cafb4c2dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Sodium-Glucose Transporter 2 Inhibitors
187 rdf:type schema:DefinedTerm
188 Nb495d32894e04b4db692cf5a12ffdffb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Middle Aged
190 rdf:type schema:DefinedTerm
191 Nb58c8e98f7e8412894da7a270964cbdf rdf:first sg:person.01232501740.42
192 rdf:rest Nbc9c3ab87bae4c4ba9a368ebd57a0ca8
193 Nba4365c82c0a4c4ebb79658e3ccdd550 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name United States
195 rdf:type schema:DefinedTerm
196 Nbc9c3ab87bae4c4ba9a368ebd57a0ca8 rdf:first sg:person.0637110453.18
197 rdf:rest N2063f8d8331143c18ac3976c67c91a09
198 Nbe16eb71cddd435b8a8512b8eb0a70db schema:name doi
199 schema:value 10.1007/s12325-019-01043-z
200 rdf:type schema:PropertyValue
201 Nc31c4a3dc60245d987aad679f6a80fbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Female
203 rdf:type schema:DefinedTerm
204 Nc428835ba90a400ca15544cab29748a5 rdf:first sg:person.01026702544.26
205 rdf:rest Nb58c8e98f7e8412894da7a270964cbdf
206 Nc8d65dc4b636476898485c02045de4ca schema:name Springer Nature - SN SciGraph project
207 rdf:type schema:Organization
208 Nce289f0332f5494d8478060a7bf5b198 rdf:first sg:person.0642244236.63
209 rdf:rest rdf:nil
210 Nd12ed3a937ed4aada5fc2c0a68f0398e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Humans
212 rdf:type schema:DefinedTerm
213 Ne275c273769845cfa056c419cb0f56fe rdf:first sg:person.010041300312.03
214 rdf:rest N3968a71f609f44b2aff38e74c0d3233b
215 Ne57ae46fabb04809b99e779846c9996b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Glucosides
217 rdf:type schema:DefinedTerm
218 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
219 schema:name Medical and Health Sciences
220 rdf:type schema:DefinedTerm
221 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
222 schema:name Clinical Sciences
223 rdf:type schema:DefinedTerm
224 sg:journal.1096634 schema:issn 0741-238X
225 1865-8652
226 schema:name Advances in Therapy
227 schema:publisher Springer Nature
228 rdf:type schema:Periodical
229 sg:person.010035354133.81 schema:affiliation grid-institutes:None
230 schema:familyName Tuccinardi
231 schema:givenName Franco
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010035354133.81
233 rdf:type schema:Person
234 sg:person.010041300312.03 schema:affiliation grid-institutes:grid.512242.2
235 schema:familyName Rossi
236 schema:givenName Maria C.
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010041300312.03
238 rdf:type schema:Person
239 sg:person.01026702544.26 schema:affiliation grid-institutes:grid.460062.6
240 schema:familyName Candido
241 schema:givenName Riccardo
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026702544.26
243 rdf:type schema:Person
244 sg:person.01112613263.43 schema:affiliation grid-institutes:grid.512242.2
245 schema:familyName Nicolucci
246 schema:givenName Antonio
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112613263.43
248 rdf:type schema:Person
249 sg:person.01232501740.42 schema:affiliation grid-institutes:grid.10438.3e
250 schema:familyName Cucinotta
251 schema:givenName Domenico
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232501740.42
253 rdf:type schema:Person
254 sg:person.0637110453.18 schema:affiliation grid-institutes:grid.512242.2
255 schema:familyName Graziano
256 schema:givenName Giusi
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637110453.18
258 rdf:type schema:Person
259 sg:person.0642244236.63 schema:affiliation grid-institutes:None
260 schema:familyName Manicardi
261 schema:givenName Valeria
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0642244236.63
263 rdf:type schema:Person
264 sg:pub.10.1007/s00125-015-3547-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048430137
265 https://doi.org/10.1007/s00125-015-3547-2
266 rdf:type schema:CreativeWork
267 sg:pub.10.1007/s00125-019-4839-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112731482
268 https://doi.org/10.1007/s00125-019-4839-8
269 rdf:type schema:CreativeWork
270 sg:pub.10.1007/s00592-014-0688-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027960230
271 https://doi.org/10.1007/s00592-014-0688-6
272 rdf:type schema:CreativeWork
273 grid-institutes:None schema:alternateName AMD Annals Coordinator, Reggio Emilia, Italy
274 Struttura Complessa Diabetologia, Ospedale di Formia, Azienda USL Latina, Formia, Italy
275 schema:name AMD Annals Coordinator, Reggio Emilia, Italy
276 Struttura Complessa Diabetologia, Ospedale di Formia, Azienda USL Latina, Formia, Italy
277 rdf:type schema:Organization
278 grid-institutes:grid.10438.3e schema:alternateName Dipartimento di Medicina Clinica e Sperimentale, Università di Messina, Messina, Italy
279 schema:name Dipartimento di Medicina Clinica e Sperimentale, Università di Messina, Messina, Italy
280 rdf:type schema:Organization
281 grid-institutes:grid.414266.3 schema:alternateName Struttura Semplice Diabetologia e Malattie Metaboliche “Giovanni Segalini”, Ospedale Bassini, Cinisello Balsamo, ASST Nord Milano, Miano, Italy
282 schema:name Struttura Semplice Diabetologia e Malattie Metaboliche “Giovanni Segalini”, Ospedale Bassini, Cinisello Balsamo, ASST Nord Milano, Miano, Italy
283 rdf:type schema:Organization
284 grid-institutes:grid.460062.6 schema:alternateName Centro Diabetologico Distretto 3, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy
285 schema:name Centro Diabetologico Distretto 3, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy
286 rdf:type schema:Organization
287 grid-institutes:grid.512242.2 schema:alternateName CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy
288 schema:name CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy
289 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...